What if the secret of health lies at the center of disease?

At Sonata, we are designing Network Medicines™ that reprogram diseased cells to become the coordinators of cure.
hero cell image with lines

About Sonata

Sonata Therapeutics is pioneering the development of Network Medicines™, a new class of therapeutics that reprogram diseased cells to release a defined array of signals that precisely coordinate multicellular networks to drive disease resolution.

In cancer, fibrosis and many other disorders, diseased cells are programmed to send pathologic signals to a network of other cell types—immune cells, fibroblasts, healthy tissues cells, etc.—perpetuating a cycle of dysfunction and disease progression. Sonata’s Network Medicines are designed to have both a direct effect on diseased cells themselves and a network effect by reprogramming those diseased cells to release a specific mix of therapeutic signals that coordinate the key cells in the network to drive disease resolution. We turn diseased cells into the coordinators of cure.

Learn more about Sonata from our CEO
Flagship CEO Chat - Volker Herrmann CEO of Sonata Therapeutics

Our Science

Rather than just targeting one cell type like most therapeutics, Network Medicines coordinate all key players in a disease network to work together to drive disease resolution.

It is well established that multicellular networks often play an important role in disease initiation and progression.  Yet drug development has traditionally focused on affecting only one cell type in the network.  Our Network Medicines are the first therapeutics specifically designed to reprogram diseased cells to release signals that modulate and coordinate all key players in the multicellular networks towards cure.

This paradigm shift in drug development—evaluating and drugging targets based on both their direct effects on the diseased cell and their ability to release a precise mix of signals that coordinate all the key cells in the multicellular network—aims to significantly advance the field of oncology, fibrosis and many other disorders where multicellular networks play a role in disease initiation and progression.

scientist in lab - our science section
woman in lab - cell images - our platform section

Our Platform

Know, Don’t Guess™

Developing an entirely new class of therapeutics requires a fundamentally new approach to drug discovery.  We always start our drug discovery process with a specific indication in mind because we know that context matters. Our Network Medicines Platform systematically and holistically defines and assesses for Network Effects necessary to drive disease resolution upfront, enabling us to select targets with desirable Network Effects at the very beginning of the drug development process.

This upfront assessment yields better, earlier decision making throughout the drug development process regarding target selection, indications, patients and potential therapy combinations.  By knowing and selecting for Network Effects upfront, each Network Medicines we will take into the clinic has an inherently higher probability of success.

Our Leadership

Backed by decades of successful drug discovery, drug development and value creation experience, our team leads with a passion and sense of urgency to rapidly bring our innovative therapeutics to patients in need.

background imageVolker Herrmann
Sonata Founding Team Member, Chief Executive Officer and President
background imageFrancesco Marincola, M.D.
Chief Scientific Officer
background imageErik Hett, Ph.D.
Chief Technology Officer
background image
Senior Vice President, Head of Drug Discovery
background imageMichael Crescenzi, MBA
Vice President, Strategy & Business Development
background imageMelissa Myint
Vice President, Head of Exploratory Biology
background imageJoyce Hu, Ph.D.
background imageNathan Edwards
Vice President, Finance

Board of Directors

David Khougazian, MBA
Sonata Chairman, Executive Partner, Growth, Flagship Pioneering
Doug Cole, M.D.
Sonata Founding Team Member, Managing Partner, Flagship Pioneering
Volker Herrmann, M.D., MBA
Sonata Founding Team Member, Chief Executive Officer and President
John Hohneker, M.D.
Former SVP, Global Head of Development, Novartis
Michael Rosenblatt, M.D.
Senior Advisor, Flagship Pioneering, Former CMO, Flagship & Merck
David Scadden, M.D.
Harvard University, Massachusetts General Hospital, Director, Center for Regenerative Medicine

Scientific Advisors & Collaborators

Peter J. Gough, D.Phil
Chief Scientific Officer, Nimble Therapeutics
Doug Green, Ph.D.
St. Jude’s, Chair Immunology
Marcella Maus, M.D., Ph.D.
HMS; Director of Cellular Immunotherapy, Mass General Cancer Center
Yury Popov, M.D., Ph.D.
Harvard/Beth Israel Deaconess Medical Center, Gastroenterology
Dave Tuveson, M.D., Ph.D.
Cancer Center Director, Cold Spring Harbor Laboratory


employees in office -work at sonata section

Work at Sonata

At Sonata, we are a dynamic, collaborative, and enthusiastic team dedicated to developing drugs that will have significant patient impact. We are looking for individuals with a passion for paradigm-changing ideas to join us.

Contact us

Interested in learning more? We’d love to hear from you.

Scroll to Top